Efficacy and safety of rituximab in common variable immunodeficiency‐associated immune cytopenias: a retrospective multicentre study on 33 patients
Open Access
- 8 October 2011
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 155 (4), 498-508
- https://doi.org/10.1111/j.1365-2141.2011.08880.x
Abstract
Patients with common variable immunodeficiency (CVID) are at high risk of developing immune thrombocytopenia (ITP) and/or autoimmune haemolytic anaemia (AHA). Given their underlying immunodeficiency, immunosuppressive treatment of these manifestations may increase the risk of infection. To assess efficacy and safety of rituximab in patients with CVID‐associated ITP/AHA, a multicentre retrospective study was performed. Thirty‐three patients, 29 adults and four children, were included. Patients received an average of 2·6 treatments prior to rituximab including steroids, intravenous immunoglobulin and splenectomy (21%). The median ITP/AHA duration at time of first rituximab administration was 12 months [range 1–324] and the indication for using rituximab was ITP (22 cases), AHA (n = 5) or both (n = 7); 1 patient was treated sequentially for ITP and then AHA. The overall initial response rate to rituximab was 85% including 74% complete responses. After a mean follow‐up of 39 ± 30 months after rituximab first administration, 10 of the initial responders relapsed and re‐treatment with rituximab was successful in 7/9. Severe infections occurred after rituximab in eight adults (24%), four of whom were not on immunoglobulin replacement therapy. In conclusion, rituximab appears to be highly effective and relatively safe for the management of CVID‐associated severe immune cytopenias.Keywords
This publication has 33 references indexed in Scilit:
- Effector and regulatory B cells: modulators of CD4+ T cell immunityNature Reviews Immunology, 2010
- Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working groupBlood, 2009
- Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodiesCurrent Opinion in Immunology, 2008
- Response of refractory immune thrombocytopenic purpura in a patient with common variable immunodeficiency to treatment with rituximabJournal of Clinical Pathology, 2007
- Rituximab for the treatment of autoimmune cytopenias in children with immune deficiencyBritish Journal of Haematology, 2007
- Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID)Journal of Autoimmunity, 2005
- Partial Response to Anti-CD20 Monoclonal Antibody Treatment of Severe Immune Thrombocytopenic Purpura in a Patient with Common Variable ImmunodeficiencyAnnals of the New York Academy of Sciences, 2005
- Autoimmune Thrombocytopenic Purpura and Common Variable ImmunodeficiencyMedicine, 2004
- The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpuraBritish Journal of Haematology, 2004
- Hematologic complications of primary immune deficienciesBlood Reviews, 2002